Radiation Oncology

EGFR+

Questions discussed in this category

How do you approach EGFR mutated NSCLC with isolated progression in the chest who is planned for a course of radiation at least 3-4 weeks?

How do you balance the risk of an EGFR flare while holding osimertinib vs the risk of pneumonitis when continuing?

1 Answer available

How many days do you hold osimertinib during or around SBRT for oligometastatic EGFR mutated advanced lung cancer?

Does the site of treatment factor into your decision?

2 Answers available

In locally advanced EGFR-mutated NSCLC with initial good response to osimertinib, how do you manage local progression of the primary?

Would you consider SBRT and continue osimertinib?

2 Answers available

Are you offering durvalumab to patients with Stage III NSCLC with known targeted mutations (ie ALK, EGFR, ROS1, BRAF) after completion of chemoradiation per PACIFIC?

The EGFR subgroup appeared not have benefited as much as other patients in the publication. However, recently it was reported that the PACIFIC study m...

1 Answer available

Is PORT recommended for incidentally found N2+ NSCLC after lobectomy for oligoprogressive metastatic NSCLC?

Does EGFR+ status influence your decision? What is the significance of this finding and its potential for progression? Is it simply occult disease con...

1 Answer available

Papers discussed in this category

The New England journal of medicine, 2018-12-13

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.

Clin Oncol (R Coll Radiol), 2017 Nov 16

Oligoprogressive Oncogene-addicted Lung Tumours: Does Stereotactic Body Radiotherapy Have a Role? Introducing the HALT Trial.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014-06

Radiation pneumonitis in patients with non--small-cell lung cancer treated with erlotinib concurrent with thoracic radiotherapy.

Radiother Oncol, 2020 Jul 31

An especially high rate of radiation pneumonitis observed in patients treated with thoracic radiotherapy and simultaneous osimertinib.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2011-10-01

Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015-01

A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG).

Lung Cancer, 2020 Nov 13

Disease flare of leptomeningeal metastases without radiological and cytological findings after the discontinuation of osimertinib.

Neuropathology, 2019 Mar 13

Rapidly progressive miliary brain metastasis of lung cancer after EGFR tyrosine kinase inhibitor discontinuation: An autopsy report.

Respir Investig, 2014 Nov 13

Disease flare after gefitinib discontinuation.

Related Topics in Radiation Oncology